TW200503666A - Treatment of type 1 diabetes with pde5 inhibitors - Google Patents

Treatment of type 1 diabetes with pde5 inhibitors

Info

Publication number
TW200503666A
TW200503666A TW093107099A TW93107099A TW200503666A TW 200503666 A TW200503666 A TW 200503666A TW 093107099 A TW093107099 A TW 093107099A TW 93107099 A TW93107099 A TW 93107099A TW 200503666 A TW200503666 A TW 200503666A
Authority
TW
Taiwan
Prior art keywords
diabetes
type
treatment
pde5 inhibitors
substantial
Prior art date
Application number
TW093107099A
Other languages
English (en)
Chinese (zh)
Inventor
Gillian Munro Burgess
Earl Michael Gibbs
Christopher Peter Wayman
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TW200503666A publication Critical patent/TW200503666A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW093107099A 2003-03-17 2004-03-17 Treatment of type 1 diabetes with pde5 inhibitors TW200503666A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45527703P 2003-03-17 2003-03-17

Publications (1)

Publication Number Publication Date
TW200503666A true TW200503666A (en) 2005-02-01

Family

ID=33029981

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093107099A TW200503666A (en) 2003-03-17 2004-03-17 Treatment of type 1 diabetes with pde5 inhibitors

Country Status (7)

Country Link
EP (1) EP1605925A1 (fr)
JP (1) JP2006520777A (fr)
BR (1) BRPI0408500A (fr)
CA (1) CA2519357A1 (fr)
MX (1) MXPA05009242A (fr)
TW (1) TW200503666A (fr)
WO (1) WO2004082667A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005235306B2 (en) * 2004-04-19 2008-08-21 Loma Linda University Composition and method of decreasing renal ischemic damage
WO2007010337A2 (fr) * 2005-07-15 2007-01-25 Proxomed Medizintechnik Gmbh Utilisation d'inhibiteurs de phosphodiesterase type 5 pour la prevention et le traitement de maladies ou de troubles, et systemes d'administration associes
MX2008001597A (es) * 2005-08-04 2008-04-04 Transform Pharmaceuticals Inc Formulaciones novedosas que comprenden fenofibrato y una estatina y metodos relacionados de tratamiento.
US20100179131A1 (en) 2006-09-07 2010-07-15 Nycomed Gmbh Combination treatment for diabetes mellitus
EP2152663B1 (fr) 2007-06-04 2014-03-19 Ben Gurion University of the Negev Research and Development Authority Composés triarylés et compositions les comprenant
SG10201709195TA (en) * 2012-11-13 2017-12-28 Nusirt Sciences Inc Compositions and methods for increasing energy metabolism
JP6154025B2 (ja) 2012-12-24 2017-06-28 ニューロガストルクス，インコーポレイテッド Ｇｉ管障害を治療するための方法
WO2015068156A1 (fr) 2013-11-05 2015-05-14 Ben-Gurion University Of The Negev Research And Development Authority Composés pour le traitement du diabète et des complications pathologiques qui en résultent
US9844554B2 (en) 2014-06-24 2017-12-19 Neurogastrx, Inc. Prodrugs of metopimazine
MX2017016930A (es) * 2017-12-19 2019-06-20 Malesil Research & Tech Llc Uso del maleato de sildenafil en el tratamiento de ulceras de pie diabetico.
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2346937A1 (fr) * 1998-10-15 2000-04-27 Per O. G. Arkhammar Interventions therapeutiques specifiques obtenues par interference avec redistribution et ou ciblage
KR100353014B1 (ko) * 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
DE19944161A1 (de) * 1999-09-15 2001-03-22 Bayer Ag Neue Kombination zur Behandlung von sexueller Dysfunktion
GB0000561D0 (en) * 2000-01-11 2000-03-01 Pfizer Ltd Treatment of diabetic ulcers
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
NZ523108A (en) * 2000-06-30 2005-04-29 Pfizer Method of treating diabetic complications i.e. peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies with cGMP PDE5 inhibitors such as sildenafil
CA2419033A1 (fr) * 2000-08-11 2002-02-21 Earl Michael Gibbs Traitement du syndrome de la resistance a l'insuline
MXPA03006936A (es) * 2001-02-02 2003-11-18 Pfizer Tratamiento de diabetes mellitus.
MXPA03006310A (es) * 2001-03-16 2003-09-16 Pfizer Compuestos farmaceuticamente activos.
GB0106631D0 (en) * 2001-03-16 2001-05-09 Pfizer Ltd Pharmaceutically active compounds
US6479493B1 (en) * 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
US20030114469A1 (en) * 2001-09-27 2003-06-19 Cohen David Saul Combinations

Also Published As

Publication number Publication date
EP1605925A1 (fr) 2005-12-21
MXPA05009242A (es) 2006-04-18
BRPI0408500A (pt) 2006-03-07
JP2006520777A (ja) 2006-09-14
WO2004082667A1 (fr) 2004-09-30
CA2519357A1 (fr) 2004-09-30

Similar Documents

Publication Publication Date Title
WO2006029036A3 (fr) Therapie combinee avec du glatiramere acetate et de la n-acetylcysteine pour traiter la sclerose en plaques
TW200510349A (en) Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
AU2003268144A1 (en) Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist
IN2005KO00312A (fr)
HK1086186A1 (en) Use of spongosine (2-methoxyadenosein) for preparing pharmaceutical for the treatment of pain
TW200616644A (en) Medicine for prevention or treatment of diabetes
WO2004103297A3 (fr) Polytherapie a base d'acetate de glatiramer et de mitoxantrone destinee au traitement de la sclerose en plaques
WO2004110380A3 (fr) Traitement des maladies a mediation immunologique au moyen de composes a base de vitamine d active, seuls ou en association avec d'autres agents therapeutiques
AU4258101A (en) Combination therapies with vascular damaging activity
WO2003092606A3 (fr) Inhibiteurs de cholinesterase pour prevenir les blessures causees par des produits chimiques
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
PL1656131T3 (pl) Zastosowanie betainy w leczeniu chromania przestankowego
WO2004006849A3 (fr) Combinaisons de medicaments pour le traitement de neoplasmes
TW200503676A (en) Use of kynurenine 3-hydroxylase inhibitors for the treatment of diabetes
EP1695969A4 (fr) Derives d'acides alpha-amino et leur utilisation comme medicaments
TW200603792A (en) Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors
WO2008060535A3 (fr) Utilisation de la reversine et de ses analogues pour le traitement du cancer
TW200642688A (en) New use of PDE7 inhibitors
MXPA05004920A (es) Combinacion que comprende un inhibidor cdk y cisplatin.
GB0313386D0 (en) Treatment of disease
TW200610524A (en) Medicine for prevention or treatment of diabetes
TW200501958A (en) A therapeutic agent for treating a behavioral disorder
TW200608965A (en) Medicine for prevention or treatment of diabetes
BRPI0407574A (pt) combinações farmacêuticas que compreendem um inibidor de nos e um antagonista de receptor de nmda